News - Skyepharma


Current filters:


Popular Filters

Skyepharma launches Flutiform in France for asthma


UK drug delivery specialist Skyepharma has received regulatory approval and agreement on pricing reimbursement…

FlutiformFranceMarkets & MarketingMundipharmaPharmaceuticalRespiratory and PulmonarySkyepharma

Kyorin expects $10 million sales after Flutiform launch in Japan for asthma

Kyorin expects $10 million sales after Flutiform launch in Japan for asthma


UK drug delivery specialist Skyepharma (LSE: SKP) has announced that Flutiform has been launched in Japan…

Asia-PacificFlutiformKyorin PharmaceuticalsLicensingPharmaceuticalRegulationRespiratory and PulmonarySkyepharma

Flutiform trial for COPD initiated in Europe

Flutiform trial for COPD initiated in Europe


UK drug delivery specialist Skyepharma (LSE: SKP) and privately-held Swiss drugmaker Mundipharma, which…

FlutiformMundipharmaPharmaceuticalResearchRespiratory and PulmonarySkyepharma

Skyepharma's asthma drug helps revenues soar 58% in first half


UK drug delivery specialist Skyepharma (LSE: SKP) has seen its first half revenues soar 58% to £31.3…


Flutiform recommended for approval in Japan


UK drug delivery specialist Skyepharma (LSE SKP) revealed yesterday (July 31) that the Pharmaceutical…

Asia-PacificFlutiformKyorin PharmaceuticalsPharmaceuticalRegulationRespiratory and PulmonarySkyepharma

FDA approves Theravance and GSK's Breo Ellipta to treat COPD


The US Food and Drug Administration on Friday (May 10) approved Breo Ellipta (fluticasone furoate, an…

BiotechnologyBreo ElliptaGlaxoSmithKlineNorth AmericaPharmaceuticalRegulationRespiratory and PulmonarySkyepharmaTheravance Biopharma

SkyePharma partner Kyorin files for Flutiform approval in Japan


UK drug delivery specialist SkyePharma (LSE: SKP) says that its Japanese development and marketing partner…

Asia-PacificFlutiformKyorin PharmaceuticalsNapp PharmaceuticalsPharmaceuticalRegulationRespiratory and PulmonarySkyepharma

SkyePharma/Mundipharma's Flutiform launched in Germany


UK-based drug delivery specialist SkyePharma (LSE: SKP) last Friday announced the launch of Flutiform,…

EuropeFlutiformMarkets & MarketingMundipharmaPharmaceuticalRespiratory and PulmonarySkyepharma

Flutiform receives UK regulatory approval; solid financials from SkyePharma


UK-based drug delivery specialist SkyePharma (LSE: SKP) yesterday announced that the UK the Medicines…

FinancialFlutiformMundipharmaPharmaceuticalRegulationRespiratory and PulmonarySkyepharma

European approval for Mundipharma/SkyePharma's asthma drug Flutiform


After some delays, the European Commission has now adopted a legally binding decision in favor of granting…

EuropeFlutiformMundipharmaPharmaceuticalRegulationRespiratory and PulmonarySkyepharma

SkyePharma partner Kyorin completes Japanese Flutiform clinical program


UK drug delivery specialist SkyePharma (LSE: SKP) saw its shares leap nearly 11% to £76.50 last…

Asia-PacificFlutiformKyorin PharmaceuticalsPharmaceuticalRegulationResearchRespiratory and PulmonarySkyepharma

Two hurdles to jump for SkyePharma, as it changes CEO


On the same day that UK-based SkyePharma (LSE: SKP) announced that Axel Mueller has resigned as chief…

3MEuropeFinancialFlutiformManagementPharmaceuticalRegulationRespiratory and PulmonarySkyepharma

Skyepharma updates on Exparel, Flutiform and financial position


UK drug developer SkyePharma (LSE: SKP) yesterday issued an update on its R&D pipeline and provided an…

Anti-Arthritics/RheumaticsExparelFinancialFlutiformLodotraPharmaceuticalRegulationResearchRespiratory and PulmonarySkyepharma

Pacira and SkyePharma leap as FDA approves painkiller Exparel


New Jersey, USA-based Pacira Pharmaceuticals (Nasdaq: PCRX) and UK drugmaker SkyePharma (LSE: SKP) both…

ExparelFinancialNeurologicalNorth AmericaPacira PharmaceuticalsPharmaceuticalRegulationSkyepharma

Flutiform review to take longer than expected, says SkyePharma


UK-based SkyePharma (LSE: SKP) revealed yesterday that the review of the European Marketing Authorization…

EuropeFlutiformMundi InternationalPharmaceuticalRegulationRespiratory and PulmonarySkyepharma

Exec appointments at SkyePharma, Impax, Ariad and Regeneron


UK-based drug delivery specialist SkyePharma (LSE: SKP) has appointed Pierre Delavaud as executive vice…

Ariad PharmaceuticalsGenericsImpax LaboratoriesManagementPharmaceuticalRegeneronSkyepharma

SkyePharma seeks funding partner for diabetes product candidate


Having completed an initial proof-of-concept study for its diabetes care product candidate, SKP-1052,…


SkyePharma in manufacturing alliance with Aenova Group; amends CRC finance facility


UK drug firm SkyePharma PLC (LSE: SKP) has agreed terms to enter into an alliance with the Aenova Group…


Sanofi gets rights to SkyePharma’s Flutiform in Mexico, Central and South America


UK-based SkyePharma (LSE: SKP) says it has entered into an exclusive development, license and marketing…

FlutiformLicensingPharmaceuticalRespiratory and PulmonarySanofiSkyepharmaSouth America

Back to top